Galli Jonathan, Greenlee John
Department of Neurology, University of Utah, Salt Lake City, UT, 84108, USA.
2. George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, 84148, USA.
F1000Res. 2020 Mar 6;9. doi: 10.12688/f1000research.21309.1. eCollection 2020.
Paraneoplastic neurological syndromes are nonmetastatic complications of malignancy secondary to immune-mediated neuronal dysfunction or death. Pathogenesis may occur from cell surface binding of antineuronal antibodies leading to dysfunction of the target protein, or from antibodies binding against intracellular antigens which ultimately leads to cell death. There are several classical neurological paraneoplastic phenotypes including subacute cerebellar degeneration, limbic encephalitis, encephalomyelitis, and dorsal sensory neuropathy. The patient's clinical presentations may be suggestive to the treating clinician as to the specific underlying paraneoplastic antibody. Specific antibodies often correlate with the specific underlying tumor type, and malignancy screening is essential in all patients with paraneoplastic neurological disease. Prompt initiation of immunotherapy is essential in the treatment of patients with paraneoplastic neurological disease, often more effective in cell surface antibodies in comparison to intracellular antibodies, as is removal of the underlying tumor.
副肿瘤性神经系统综合征是恶性肿瘤的非转移性并发症,继发于免疫介导的神经元功能障碍或死亡。发病机制可能源于抗神经元抗体与细胞表面结合导致靶蛋白功能障碍,或源于抗体与细胞内抗原结合最终导致细胞死亡。有几种经典的神经系统副肿瘤表型,包括亚急性小脑变性、边缘叶脑炎、脑脊髓炎和背根感觉神经病。患者的临床表现可能会提示治疗医生具体的潜在副肿瘤抗体。特定抗体通常与特定的潜在肿瘤类型相关,对所有副肿瘤性神经系统疾病患者进行恶性肿瘤筛查至关重要。对于副肿瘤性神经系统疾病患者,及时启动免疫治疗至关重要,与细胞内抗体相比,免疫治疗对细胞表面抗体通常更有效,切除潜在肿瘤也是如此。